Warburg Research Analysts Give Fresenius SE & Co KGaA (FRA:FRE) a €80.00 Price Target

Share on StockTwits

Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €80.00 ($93.02) price objective by analysts at Warburg Research in a research note issued to investors on Wednesday, October 17th. The firm presently has a “buy” rating on the stock. Warburg Research’s target price would suggest a potential upside of 51.46% from the company’s previous close.

A number of other equities research analysts have also weighed in on FRE. Berenberg Bank set a €81.85 ($95.17) target price on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Tuesday, July 31st. UBS Group set a €59.00 ($68.60) target price on Fresenius SE & Co KGaA and gave the company a “sell” rating in a research report on Tuesday, June 26th. Goldman Sachs Group set a €72.00 ($83.72) price target on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research report on Tuesday, July 31st. Sanford C. Bernstein set a €83.00 ($96.51) target price on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Tuesday, July 3rd. Finally, Independent Research set a €80.00 ($93.02) price target on Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Tuesday, July 31st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of €74.20 ($86.28).

FRE traded down €1.54 ($1.79) during trading hours on Wednesday, reaching €52.82 ($61.42). 2,522,764 shares of the company’s stock traded hands. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($69.95) and a 52-week high of €80.00 ($93.02).

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Read More: What are the most popular ETFs

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.